Final phase II results are expected later in the year and the company has yet to begin the final step toward approval, a phase III trial of the drug
This ensures the benefits of treatment outweigh the risks and that medication is given as part of a holistic weight management plan
Nausea is the most common side effect, affecting 20 to 44% of users across GLP-1 medications per FDA prescribing information for Wegovy, Zepbound, and Ozempic
This finding and those of our study would pave the way for leveraging the intraoperative evaluation of pericardial fluid for diagnostic/prognostic and therapeutic purposes and for molecular investigation of IHD pathogenesis
New York City, NY, May 04, 2026 (GLOBE NEWSWIRE) -- DISCLAIMER: This article is for informational purposes only and does not constitute medical advice
Purity: 99.94% CAS No.: 89030-95-5 Formula: C 14 H 22 CuN 6 O 4 Molecular Weight:401.91 Storage: Sealed storage, away from moisture and light